Regulatory Agenda

Federal RegisterJun 24, 2019

Ask Donna

What actually matters in this document.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

21 CFR Ch. I

25 CFR Ch. V

42 CFR Chs. I-V

45 CFR Subtitle A; Subtitle B, Chs. II, III, and XIII

Regulatory Agenda

AGENCY:

Office of the Secretary, HHS.

ACTION:

Semiannual Regulatory Agenda.

SUMMARY:

The Regulatory Flexibility Act of 1980 and Executive Order (E.O.) 12866 require the semiannual issuance of an inventory of rulemaking actions under development throughout the Department, offering for public review summarized information about forthcoming regulatory actions.

FOR FURTHER INFORMATION CONTACT:

Ann C. Agnew, Executive Secretary, Department of Health and Human Services, 200 Independence Avenue SW, Washington, DC 20201; (202) 690-5627.

SUPPLEMENTARY INFORMATION:

The Department of Health and Human Services (HHS) is the Federal government's lead agency for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. HHS enhances the health and well-being of Americans by promoting effective health and human services and by fostering sound, sustained advances in the sciences underlying medicine, public health, and social services.

This Agenda presents the regulatory activities that the Department expects to undertake in the foreseeable future to advance this mission. HHS has an agency-wide effort to support the Agenda's purpose of encouraging more effective public participation in the regulatory process. For example, to encourage public participation, we regularly update our regulatory web page (

http://www.HHS.gov/regulations

) which includes links to HHS rules currently open for public comment, and also provides a “regulations toolkit” with background information on regulations, the commenting process, how public comments influence the development of a rule, and how the public can provide effective comments. HHS also actively encourages meaningful public participation in its retrospective review of regulations, through a comment form on the HHS retrospective review web page (

http://www.HHS.gov/RetrospectiveReview

The rulemaking abstracts included in this paper issue of the

Federal Register

cover, as required by the Regulatory Flexibility Act of 1980, those prospective HHS rulemakings likely to have a significant economic impact on a substantial number of small entities. The Department's complete Regulatory Agenda is accessible online at

http://www.RegInfo.gov.

Ann C. Agnew,

Executive Secretary to the Department.

Office for Civil Rights—Proposed Rule Stage

Sequence No.

Title

Regulation

Identifier No.

Nondiscrimination in Health Programs or Activities

0945-AA11

Office of the National Coordinator for Health Information Technology—Proposed Rule Stage

Sequence No.

Title

Regulation

Identifier No.

21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program

0955-AA01

Food and Drug Administration—Proposed Rule Stage

Sequence No.

Title

Regulation

Identifier No.

Over-the-Counter (OTC) Drug Review—Cough/Cold (Antihistamine) Products

0910-AF31

Sunscreen Drug Products For Over-The-Counter-Human Use; Tentative Final Monograph

0910-AF43

Mammography Quality Standards Act; Amendments to Part 900 Regulations

0910-AH04

Medication Guides; Patient Medication Information

0910-AH68

Nutrient Content Claims, Definition of Term: Healthy

0910-AI13

Revocation of Uses of Partially Hydrogenated Oils in Foods

0910-AI15

Required Warnings for Cigarette Packages and Advertisements

0910-AI39

Food and Drug Administration—Final Rule Stage

Sequence No.

Title

Regulation

Identifier No.

Postmarketing Safety Reporting Requirements for Human Drug and Biological Products

0910-AA97

Food Labeling; Gluten-Free Labeling of Fermented, Hydrolyzed, or Distilled Foods

0910-AH00

Topical Antimicrobial Drug Products for Over-the-Counter Human Use: Final Monograph for Consumer Antiseptic Rub Products

0910-AH97

Milk and Cream Product and Yogurt Products, Final Rule to Revoke the Standards for Lowfat Yogurt and Nonfat and to Amend the Standard for Yogurt

0910-AI40

Food and Drug Administration—Long-Term Actions

Sequence No.

Title

Regulation

Identifier No.

Over-the-Counter (OTC) Drug Review—External Analgesic Products

0910-AF35

Over-the-Counter (OTC) Drug Review—Internal Analgesic Products

0910-AF36

Over-the-Counter (OTC) Drug Review—Laxative Drug Products

0910-AF38

Over-the-Counter (OTC) Drug Review—Weight Control Products

0910-AF45

Over-the-Counter (OTC) Drug Review—Pediatric Dosing for Cough/Cold Products

0910-AG12

Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products

0910-AG18

Sunlamp Products; Amendment to the Performance Standard

0910-AG30

General and Plastic Surgery Devices: Sunlamp Products

0910-AH14

Combinations of Bronchodilators With Expectorants; Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use

0910-AH16

Acute Nicotine Toxicity Warnings for E-Liquids

0910-AH24

Testing Standards for Batteries and Battery Management Systems in Electronic Nicotine Delivery Systems

0910-AH90

Administration Detention of Tobacco Products

0910-AI05

Food and Drug Administration—Completed Actions

Sequence No.

Title

Regulation

Identifier No.

Label Requirement for Food That Has Been Refused Admission Into the United States

0910-AF61

Laser Products; Amendment to Performance Standard

0910-AF87

Centers for Medicare & Medicaid Services—Proposed Rule Stage

Sequence No.

Title

Regulation

Identifier No.

Requirements for Long-Term Care Facilities: Regulatory Provisions to Promote Program Efficiency, Transparency, and Burden Reduction (CMS-3347-P)

(Section 610 Review)

0938-AT36

CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1715-P)

(Section 610 Review)

0938-AT72

Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals; the Long-Term Care Hospital Prospective Payment System; and FY 2020 Rates (CMS-1716-F)

(Section 610 Review)

0938-AT73

CY 2020 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1717-P)

(Section 610 Review)

0938-AT74

Centers for Medicare & Medicaid Services—Final Rule Stage

Sequence No.

Title

Regulation

Identifier No.

Hospital and Critical Access Hospital (CAH) Changes to Promote Innovation, Flexibility, and Improvement in Patient Care (CMS-3295-F)

(Rulemaking Resulting From a Section 610 Review)

0938-AS21

Centers for Medicare & Medicaid Services—Long-Term Actions

Sequence No.

Title

Regulation

Identifier No.

Durable Medical Equipment Fee Schedule, Adjustments to Resume the Transitional 50/50 Blended Rates to Provide Relief in Non-Competitive Bidding Areas (CMS-1687-F)

(Section 610 Review)

0938-AT21

Centers for Medicare & Medicaid Services—Completed Actions

Sequence No.

Title

Regulation

Identifier No.

CY 2019 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) (CMS-1691-F)

(Completion of a Section 610 Review)

0938-AT28

CY 2019 Home Health Prospective Payment System Rate Update and CY 2020 Case-Mix Adjustment Methodology Refinements; Value-Based Purchasing Model; Quality Reporting Requirements (CMS-1689-FC)

(Completion of a Section 610 Review)

0938-AT29

CY 2019 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1695-FC)

(Completion of a Section 610 Review)

0938-AT30

100

CY 2019 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B and the Quality Payment Program (CMS-1693-F)

(Completion of a Section 610 Review)

0938-AT31

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Office for Civil Rights (OCR)

Proposed Rule Stage

64. Nondiscrimination in Health Programs or Activities

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

Sec. 1557 of the Patient Protection and Affordable Care Act (42 U.S.C. 18116)

Abstract:

This proposed rule implements section 1557 of the Patient Protection and Affordable Care Act (PPACA), which prohibits discrimination on the basis of race, color, national origin, sex, age, and disability under any health program or activity, any part of which is receiving Federal financial assistance, including credits, subsidies, or contracts of insurance, or under any program or activity that is administered by an Executive Agency or any entity established under Title l of the PPACA.

Timetable:

Action

Date

FR Cite

NPRM

05/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Luben Montoya, Section Chief, Civil Rights Division, Department of Health and Human Services, Office for Civil Rights, 200 Independence Avenue SW, Washington, DC 20201,

Phone:

202 774-3041, TDD

Phone:

800 537-7697,

Email: ocrmail@hhs.gov

RIN:

0945-AA11

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Office of the National Coordinator for Health Information Technology (ONC)

Proposed Rule Stage

65. 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program

E.O. 13771 Designation:

Regulatory.

Legal Authority:

Pub. L. 114-255

Abstract:

The rulemaking would implement certain provisions of the 21st Century Cures Act, including conditions and maintenance of certification requirements for health information technology (IT) developers under the ONC Health IT Certification Program (Program), the voluntary certification of health IT for use by pediatric healthcare providers and reasonable and necessary activities that do not constitute information blocking. The rulemaking would also modify the 2015 Edition health IT certification criteria and Program in additional ways to advance interoperability, enhance health IT certification, and reduce burden and costs.

Timetable:

Action

Date

FR Cite

NPRM

03/04/19

84 FR 7424

NPRM Comment Period Extended

04/23/19

84 FR 16834

NPRM Comment Period End

05/03/19

NPRM Comment Period Extended End

06/03/19

Final Action

11/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Michael Lipinski, Director, Regulatory Affairs Division, Department of Health and Human Services, Office of the National Coordinator for Health Information Technology, Mary E. Switzer Building, 330 C Street SW, Washington, DC 20201,

Phone:

202 690-7151.

RIN:

0955-AA01

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Food and Drug Administration (FDA)

Proposed Rule Stage

66. Over-the-Counter (OTC) Drug Review—Cough/Cold (Antihistamine) Products

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

21 U.S.C. 321p; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371

Abstract:

FDA will be proposing a rule to add the common cold indication to certain over-the-counter (OTC) antihistamine active ingredients on a pilot basis. This proposed rule is the result of collaboration under the U.S.-Canada Regulatory Cooperation Council as part of efforts to reduce unnecessary duplication and differences. This pilot exercise will help determine the feasibility of developing an ongoing mechanism for alignment in review and adoption of OTC drug monograph elements.

Timetable:

Action

Date

FR Cite

Reopening of Administrative Record

08/25/00

65 FR 51780

Comment Period End

11/24/00

NPRM (Amendment) (Common Cold)

06/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Janice Adams-King, Regulatory Health Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5416, 10903 New Hampshire Avenue, Silver Spring, MD 20993,

Phone:

301 796-3713,

Fax:

301 796-9899,

Email: janice.adams-king@fda.hhs.gov

RIN:

0910-AF31

67. Sunscreen Drug Products for Over-the-Counter-Human Use; Tentative Final Monograph

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321p; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371

Abstract:

The proposed rule will address the general recognition of safety and effectiveness (GRASE) status of the 16 sunscreen monograph ingredients and describe data gaps that FDA believes need to be filled in order for FDA to permit the continued marketing

of these ingredients without submitting new drug applications for premarket review. Consistent with the Sunscreen Innovation Act, we also expect to address sunscreen dosage forms and maximum SPF values.

Timetable:

Action

Date

FR Cite

ANPRM (Sunscreen and Insect Repellent)

02/22/07

72 FR 7941

ANPRM Comment Period End

05/23/07

NPRM (UVA/UVB)

08/27/07

72 FR 49070

NPRM Comment Period End

12/26/07

Final Action (UVA/UVB)

06/17/11

76 FR 35620

NPRM (Effectiveness)

06/17/11

76 FR 35672

NPRM (Effectiveness) Comment Period End

09/15/11

ANPRM (Dosage Forms)

06/17/11

76 FR 35669

ANPRM (Dosage Forms) Comment Period End

09/15/11

NPRM

02/26/19

84 FR 6204

NPRM Comment Period End

05/28/19

Final Action

11/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Kristen Hardin, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, WO 22, Room 5491, Silver Spring, MD 20993,

Phone:

240 402-4246,

Fax:

301 796-9841,

Email: kristen.hardin@fda.hhs.gov

RIN:

0910-AF43

68. Mammography Quality Standards Act; Amendments to Part 900 Regulations

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 360i; 21 U.S.C. 360nn; 21 U.S.C. 374(e); 42 U.S.C. 263b

Abstract:

FDA is proposing to amend its regulations governing mammography. The amendments would update the regulations issued under the Mammography Quality Standards Act of 1992 (MQSA). FDA is taking this action to address changes in mammography technology and mammography processes that have occurred since the regulations were published in 1997 and to address breast density reporting to patient and health care providers.

Timetable:

Action

Date

FR Cite

NPRM

03/28/19

84 FR 11669

NPRM Comment Period End

06/26/19

Final Action

10/00/20

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Erica Payne, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, 10903 New Hampshire Avenue, WO 66, Room 5522, Silver Spring, MD 20993,

Phone:

301 796-3999,

Fax:

301 847-8145,

Email: erica.payne@fda.hhs.gov

RIN:

0910-AH04

69. Medication Guides; Patient Medication Information

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321

et seq.;

42 U.S.C. 262; 42 U.S.C. 264; 21 U.S.C. 371

Abstract:

The proposed rule would amend FDA medication guide regulations to require a new form of patient labeling, Patient Medication Information, for submission to and review by the FDA for human prescription drug products and certain blood products used, dispensed, or administered on an outpatient basis. The proposed rule would include requirements for Patient Medication Information development and distribution. The proposed rule would require clear and concisely written prescription drug product information presented in a consistent and easily understood format to help patients use their prescription drug products safely and effectively.

Timetable:

Action

Date

FR Cite

NPRM

11/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Chris Wheeler, Supervisory Project Manager, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, Building 51, Room 3330, Silver Spring, MD 20993,

Phone:

301 796-0151,

Email: chris.wheeler@fda.hhs.gov

RIN:

0910-AH68

70. Nutrient Content Claims, Definition of Term: Healthy

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 343; 21 U.S.C. 371

Abstract:

The proposed rule would update the definition for the implied nutrient content claim “healthy” to be consistent with current nutrition science and federal dietary guidelines. The proposed rule would revise the requirements for when the claim “healthy” can be voluntarily used in the labeling of human food products so that the claim reflects current science and dietary guidelines and help consumers maintain healthy dietary practices.

Timetable:

Action

Date

FR Cite

NPRM

05/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Vincent De Jesus, Nutritionist, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, (HFS-830), Room 3D-031, 5100 Paint Branch Parkway, College Park, MD 20740,

Phone:

240 402-1774,

Fax:

301 436-1191,

Email: vincent.dejesus@fda.hhs.gov.

RIN:

0910-AI13

71. Revocation of Uses of Partially Hydrogenated Oils in Foods

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321; 21 U.S.C. 341; 21 U.S.C. 343; 21 U.S.C. 348; 21 U.S.C. 371; 21 U.S.C. 379(e)

Abstract:

In the

Federal Register

of June 17, 2015 (80 FR 34650), we published a declaratory order announcing our final determination that there is no longer a consensus among qualified experts that partially hydrogenated oils (PHOs) are generally recognized as safe (GRAS) for any use in human food. In the

Federal Register

of May 21, 2018 (83 FR 23382), we denied a food additive petition requesting that the food additive regulations be amended to provide for the safe use of PHOs in certain food applications. We are now proposing to update our regulations to remove all mention of partially hydrogenated oils and to revoke all prior sanctioned uses. This rulemaking implements FDA's findings that the available data demonstrate that PHOs used in food may cause the food to be unsafe.

Timetable:

Action

Date

FR Cite

NPRM

11/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Ellen Anderson, Consumer Safety Officer, Department of Health and Human Services, Food and Drug Administration, HFS-265, 4300

River Road, College Park, MD 20740,

Phone:

240 402-1309,

Email: ellen.anderson@fda.hhs.gov.

RIN:

0910-AI15

72. • Required Warnings for Cigarette Packages and Advertisements

E.O. 13771 Designation:

Regulatory.

Legal Authority:

15 U.S.C. 1333; 21 U.S.C. 371; 21 U.S.C. 387c; 21 U.S.C. 387i; Secs 201 and 202, Pub. L. 111-31, 123 Stat. 1776; . . .

Abstract:

This rule would require color graphics depicting the negative health consequences of smoking to accompany textual warning statements on cigarette packages and in cigarette advertisements. As directed by Congress in the Tobacco Control Act, which amends the Federal Cigarette Labeling and Advertising Act, the rule would require these new cigarette health warnings to occupy the top 50 percent of the area of the front and rear panels of cigarette packages and at least 20 percent of the area of cigarette advertisements. The original rule FDA issued in 2011 was vacated by the U.S. Court of Appeals for the District of Columbia Circuit in August 2012 (

R.J. Reynolds Tobacco Co.

United States Food & Drug Admin.,

696 F.3d 1205 D.C. Cir. 2012).

Timetable:

Action

Date

FR Cite

NPRM

08/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Courtney Smith, Senior Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, Document Control Center, Building 71, Room G335, 10903 New Hampshire Avenue, Silver Spring, MD 20993,

Phone:

301 796-3894,

Fax:

301 595-1426,

Email: ctpregulations@fda.hhs.gov.

RIN:

0910-AI39

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Food and Drug Administration (FDA)

Final Rule Stage

73. Postmarketing Safety Reporting Requirements for Human Drug and Biological Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

42 U.S.C. 216; 42 U.S.C. 241; 42 U.S.C. 242a; 42 U.S.C. 262 and 263; 42 U.S.C. 263a to 263n; 42 U.S.C. 264; 42 U.S.C. 300aa; 21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 360b to 360j; 21 U.S.C. 361a; 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 375; 21 U.S.C. 379e; 21 U.S.C. 381

Abstract:

The final rule would amend the postmarketing safety reporting regulations for human drugs and biological products including blood and blood products in order to better align FDA requirements with guidelines of the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); and to update reporting requirements in light of current pharmacovigilance practice and safety information sources and enhance the quality of safety reports received by FDA. These revisions were proposed as part of a single rulemaking (68 FR 12406) to clarify and revise both premarketing and postmarketing safety reporting requirements for human drug and biological products. Premarketing safety reporting requirements were finalized in a separate final rule published on September 29, 2010 (75 FR 59961).

Timetable:

Action

Date

FR Cite

NPRM

03/14/03

68 FR 12406

NPRM Comment Period Extended

06/18/03

NPRM Comment Period End

07/14/03

NPRM Comment Period Extension End

10/14/03

Final Rule

09/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Jane E. Baluss, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6278, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002,

Phone:

301 796-3469,

Fax:

301 847-8440,

Email: jane.baluss@fda.hhs.gov.

RIN:

0910-AA97

74. Food Labeling; Gluten-Free Labeling of Fermented, Hydrolyzed, or Distilled Foods

E.O. 13771 Designation:

Regulatory.

Legal Authority:

Sec. 206 of the Food Allergen Labeling and Consumer Protection Act; 21 U.S.C. 343(a)(1); 21 U.S.C. 321(n); 21 U.S.C. 371(a)

Abstract:

This final rule would establish requirements concerning “gluten-free” labeling for foods that are fermented or hydrolyzed or that contain fermented or hydrolyzed ingredients. These additional requirements for the “gluten-free” labeling rule are needed to help ensure that individuals with celiac disease are not misled and receive truthful and accurate information with respect to fermented or hydrolyzed foods labeled as “gluten-free.”

Timetable:

Action

Date

FR Cite

NPRM

11/18/15

80 FR 71990

NPRM Comment Period Reopened

01/22/16

81 FR 3751

NPRM Comment Period End

02/16/16

NPRM Comment Period Reopened End

02/22/16

NPRM Comment Period Reopened

02/23/16

81 FR 8869

NPRM Comment Period Reopened End

04/25/16

Final Rule

09/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Carol D'Lima, Staff Fellow, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, Room 4D022, HFS 820, 5001 Campus Drive, College Park, MD 20740,

Phone:

240 402-2371,

Fax:

301 436-2636,

Email: carol.dlima@fda.hhs.gov.

RIN:

0910-AH00

75. Topical Antimicrobial Drug Products for Over-the-Counter Human Use: Final Monograph for Consumer Antiseptic Rub Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360 and 361; 21 U.S.C. 371; 21 U.S.C. 374 and 375; 21 U.S.C. 379; 42 U.S.C. 216; 42 U.S.C. 241 and 242; 42 U.S.C. 262

Abstract:

This final rule amends the 1994 tentative final monograph (TFM) for over-the-counter (OTC) antiseptic drug products that published in the

Federal Register

of June 17, 1994, (the 1994 TFM). The final rule is part of the ongoing review of OTC drug products conducted by FDA. In this final rule, we address whether certain active ingredients used in OTC consumer antiseptic products intended for use without water (referred to as consumer antiseptic rubs) are for evaluation under the OTC Drug Review for use in consumer antiseptic rub products.

Timetable:

Action

Date

FR Cite

Final Rule

05/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Anita Kumar, Biologist, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 10903 New Hampshire Avenue, Building 22, Room 5445, Silver Spring, MD 20993,

Phone:

301 796-1032,

Email: anita.kumar@fda.hhs.gov.

RIN:

0910-AH97

76. • Milk and Cream Product and Yogurt Products, Final Rule To Revoke the Standards for Lowfat Yogurt and Nonfat and To Amend the Standard for Yogurt

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

21 U.S.C. 321; 21 U.S.C. 336; 21 U.S.C. 341; 21 U.S.C. 343; 21 U.S.C. 348; 21 U.S.C. 371(e); 21 U.S.C. 379e

Abstract:

This final rule amends the standard for yogurt and revokes the standards for lowfat and nonfat yogurt. It modernizes the standard to allow for technological advances, to preserve the basic nature and essential characteristics of yogurt, and to promote honesty and fair dealing in the interest of consumers.

Section, 701(e)(1), of the Federal Food, Drug, and Cosmetic Act identifies that specific decisions such as the definitions and standards of identity for dairy products are to be promulgated under formal rulemaking provisions of 5 U.S.C. 556 and 557. Section 3(d) of Executive Order 12866 defines regulation to exclude regulations or rules issued in accordance with the formal rulemaking provisions of 5 U.S.C. 556 and 557; accordingly, this final rule is not subject to the requirements of Executive Order 12866. Notwithstanding this exclusion, and our standard practice not to include formal rulemaking in the Unified Agenda, we have decided to include this particular rule in the Unified Agenda in order to highlight our de-regulatory work in this space.

Timetable:

Action

Date

FR Cite

ANPRM

07/03/03

68 FR 39873

ANPRM Comment Period End

10/01/03

NPRM

01/15/09

74 FR 2443

NPRM Comment Period End

04/29/09

Final Action

09/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Terri Wenger, Food Technologist, Department of Health and Human Services, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, College Park, MD 20740,

Phone:

240 402-2371,

Email: terri.wenger@fda.hhs.gov.

RIN:

0910-AI40

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Food and Drug Administration (FDA)

Long-Term Actions

77. Over-the-Counter (OTC) Drug Review—External Analgesic Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321p; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371

Abstract:

The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective and not misbranded. After a final monograph (

i.e.,

final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. The final action addresses the 2003 proposed rule on patches, plasters, and poultices. The proposed rule will address issues not addressed in previous rulemakings.

Timetable:

Action

Date

FR Cite

NPRM

To Be Determined

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Janice Adams-King, Regulatory Project Manager, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 22, Room 5416, 10903 New Hampshire Avenue, Silver Spring, MD 20993,

Phone:

301 796-3713,

Email: janice.adams-king@fda.hhs.gov.

RIN:

0910-AF35

78. Over-the-Counter (OTC) Drug Review—Internal Analgesic Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321p; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 379e

Abstract:

The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective, and not misbranded. After a final monograph (

i.e.,

final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. The first action addresses acetaminophen safety. The second action addresses products marketed for children under 2 years old and weight- and age-based dosing for children's products.

Timetable:

Action

Date

FR Cite

NPRM (Amendment) (Required Warnings and Other Labeling)

12/26/06

71 FR 77314

NPRM Comment Period End

05/25/07

Final Action (Required Warnings and Other Labeling)

04/29/09

74 FR 19385

Final Action (Correction)

06/30/09

74 FR 31177

Final Action (Technical Amendment)

11/25/09

74 FR 61512

NPRM (Amendment) (Acetaminophen)

To Be Determined

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

301 796-3713,

Fax:

301 796-9899,

Email: janice.adams-king@fda.hhs.gov.

RIN:

0910-AF36

79. Over-the-Counter (OTC) Drug Review—Laxative Drug Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 371

Abstract:

The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective, and not misbranded. After a final monograph (

i.e.,

final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. The final rule listed will address the professional labeling for sodium phosphate drug products.

Timetable:

Action

Date

FR Cite

Final Action (Granular Psyllium)

03/29/07

72 FR 14669

Final Action Effective (Granular Psyllium)

10/01/07

NPRM (Professional Labeling—Sodium Phosphate)

02/11/11

76 FR 7743

NPRM Comment Period End

03/14/11

Final Rule

To Be Determined

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

301 796-3713,

Fax:

301 796-9899,

Email: janice.adams-king@fda.hhs.gov

RIN:

0910-AF38

80. Over-the-Counter (OTC) Drug Review—Weight Control Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321p; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371

Abstract:

The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective and not misbranded. After a final monograph (

i.e.,

final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. The final action finalizes the 2005 proposed rule for weight control products containing phenylpropanolamine.

Timetable:

Action

Date

FR Cite

NPRM (Phenylpropanolamine)

12/22/05

70 FR 75988

NPRM Comment Period End

03/22/06

NPRM (Benzocaine)

03/09/11

76 FR 12916

NPRM Comment Period End

06/07/11

Final Action (Phenylpropanolamine)

To Be Determined

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

301 796-3713,

Email: janice.adams-king@fda.hhs.gov

RIN:

0910-AF45

81. Over-the-Counter (OTC) Drug Review—Pediatric Dosing for Cough/Cold Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371

Abstract:

The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective, and not misbranded. After a final monograph (

i.e.,

final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. This action will propose changes to the final monograph to address safety and efficacy issues associated with pediatric cough and cold products.

Timetable:

Action

Date

FR Cite

NPRM

To Be Determined

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

301 796-3713,

Fax:

301 796-9899,

Email: janice.adams-king@fda.hhs.gov

RIN:

0910-AG12

82. Electronic Distribution of Prescribing Information for Human Prescription Drugs Including Biological Products

E.O. 13771 Designation:

Other.

Legal Authority:

21 U.S.C. 321; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 358; 21 U.S.C. 360; 21 U.S.C. 360b; 21 U.S.C. 360gg to 360ss; 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 379e; 42 U.S.C. 216; 42 U.S.C. 241; 42 U.S.C. 262; 42 U.S.C. 264

Abstract:

This rule would require electronic package inserts for human drug and biological prescription products with limited exceptions, in lieu of paper, which is currently used. These inserts contain prescribing information intended for healthcare practitioners. This would ensure that the information accompanying the product is the most up-to-date information regarding important safety and efficacy issues about these products.

Timetable:

Action

Date

FR Cite

NPRM

12/18/14

79 FR 75506

NPRM Comment Period Extended

03/09/15

80 FR 12364

NPRM Comment Period End

03/18/15

NPRM Comment Period Extended End

05/18/15

Final Rule

To Be Determined

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Michael Bernstein, Supervisory Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, WO 51, Room 6240, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002,

Phone:

301 796-3478,

Email: michael.bernstein@fda.hhs.gov

RIN:

0910-AG18

83. Sunlamp Products; Amendment to the Performance Standard

E.O. 13771 Designation:

Fully or Partially Exempt.

Legal Authority:

21 U.S.C. 360ii; 21 U.S.C. 360kk; 21 U.S.C. 393; 21 U.S.C. 371

Abstract:

FDA is updating the performance standard for sunlamp products to improve safety, reflect new scientific information, and work towards harmonization with international standards. By harmonizing with the International Electrotechnical Commission, this rule will decrease the regulatory burden on industry and allow the Agency to take advantage of the expertise of the international committees, thereby also saving resources.

Timetable:

Action

Date

FR Cite

NPRM

12/22/15

80 FR 79505

NPRM Comment Period End

03/21/16

Final Rule

06/00/20

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Ian Ostermiller, Regulatory Counsel, Center for Devices and Radiological Health, Department of Health and Human Services, Food and Drug Administration, 10903 New Hampshire Avenue, WO 66, Room 5454, Silver Spring, MD 20993,

Phone:

301 796-5678,

Email: ian.ostermiller@fda.hhs.gov

RIN:

0910-AG30

84. General and Plastic Surgery Devices: Sunlamp Products

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 360j(e)

Abstract:

This rule would apply device restrictions to sunlamp products. Sunlamp products include ultraviolet (UV) lamps and UV tanning beds and booths. The incidence of skin cancer, including melanoma, has been increasing, and a large number of skin cancer cases are attributable to the use of sunlamp products. The devices may cause about 400,000 cases of skin cancer per year, and 6,000 of which are melanoma. Beginning use of sunlamp products at young ages, as well as frequently using sunlamp products, both increases the risk of developing skin cancers and other illnesses, and sustaining other injuries. Even infrequent use, particularly at younger ages, can significantly increase these risks.This rule would apply device restrictions to sunlamp products.

Timetable:

Action

Date

FR Cite

NPRM

12/22/15

80 FR 79493

NPRM Comment Period End

03/21/16

Final Rule

06/00/20

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

301 796-5678,

Email: ian.ostermiller@fda.hhs.gov

RIN:

0910-AH14

85. Combinations of Bronchodilators With Expectorants; Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 321p; 21 U.S.C. 331; 21 U.S.C. 351 to 353; 21 U.S.C. 355; 21 U.S.C. 360; 21 U.S.C. 371

Abstract:

The OTC drug review establishes conditions under which OTC drugs are considered generally recognized as safe and effective, and not misbranded. After a final monograph (

i.e.,

final rule) is issued, only OTC drugs meeting the conditions of the monograph, or having an approved new drug application, may be legally marketed. These actions address cough/cold drug products containing an oral bronchodilator (ephedrine and its salts) in combination with any expectorant.

Timetable:

Action

Date

FR Cite

NPRM (Amendment)

07/13/05

70 FR 40232

NPRM Comment Period End

11/10/05

Final Action (Technical Amendment)

03/19/07

72 FR 12730

Final Rule

To Be Determined

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

301 796-3713,

Fax:

301 796-9899,

Email: janice.adams-king@fda.hhs.gov

RIN:

0910-AH16

86. Acute Nicotine Toxicity Warnings for E-Liquids

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 301

et seq.;

21 U.S.C. 331; 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 387

Abstract:

This rule would establish nicotine exposure warning requirements for liquid nicotine and nicotine-containing e-liquid(s) that are made or derived from tobacco and intended for human consumption, and potentially for other tobacco products including, but not limited to, novel tobacco products such as dissolvables, lotions, gels, and drinks. This action is intended to protect users and non-users from accidental exposures to nicotine-containing e-liquids in tobacco products.

Timetable:

Action

Date

FR Cite

NPRM

03/00/21

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

301 796-3894,

Fax:

301 595-1426,

Email: ctpregulations@fda.hhs.gov

RIN:

0910-AH24

87. Testing Standards for Batteries and Battery Management Systems in Electronic Nicotine Delivery Systems

E.O. 13771 Designation:

Regulatory.

Legal Authority:

21 U.S.C. 301 et. seq.; 21 U.S.C. 371; 21 U.S.C. 387(b); 21 U.S.C. 387(g); 21 U.S.C. 387i

Abstract:

This rule would propose to establish a product standard to require testing standards for batteries used in electronic nicotine delivery systems (ENDS) and require design protections including a battery management system for ENDS using batteries and protective housing for replaceable batteries. This product standard would protect the safety of users of battery-powered tobacco products and will help to streamline the FDA premarket review process, ultimately reducing the burden on both manufacturers and the Agency. The proposed rule would be applicable to tobacco products that include a non-user replaceable battery as well as products that include a user replaceable battery.

Timetable:

Action

Date

FR Cite

NPRM

05/00/20

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Darin Achilles, Regulatory Counsel, Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products, 10903 New Hampshire Avenue, Document Control Center, Building 71, Room G335, Silver Spring, MD 20993,

Phone:

877 287-1373,

Fax:

301 595-1426,

Email: ctpregulations@fda.hhs.gov

RIN:

0910-AH90

88. Administration Detention of Tobacco Products

E.O. 13771 Designation:

Other.

Legal Authority:

21 U.S.C. 334; 21 U.S.C. 371

Abstract:

The Food and Drug Administration (FDA) is proposing regulations to establish requirements for the administrative detention of tobacco products. This action, if finalized, would allow FDA to administratively detain tobacco products encountered during inspections that an officer or employee conducting the inspection has reason to believe are adulterated or misbranded. The intent of administrative detention is to protect public health by preventing the distribution or use of violative tobacco products until FDA has had time to consider the appropriate action to take and, where appropriate, to initiate a regulatory action.

Timetable:

Action

Date

FR Cite

NPRM

08/00/20

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

877 287-1373,

Fax:

301 595-1426,

Email: ctpregulations@fda.hhs.gov

RIN:

0910-AI05

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Food and Drug Administration (FDA)

Completed Actions

89. Label Requirement for Food That Has Been Refused Admission Into the United States

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

15 U.S.C. 1453 to 1455; 21 U.S.C. 321; 21 U.S.C. 342 and 343; 21 U.S.C. 371; 21 U.S.C. 374; 21 U.S.C. 381; 42 U.S.C. 216; 42 U.S.C. 264

Abstract:

On September 18, 2008, FDA issued a proposed rule that would have required owners or consignees to label imported food that was refused entry into the United States. FDA does not plan to finalize the rule.

Completed:

Reason

Date

FR Cite

NPRM; Withdrawal

09/28/18

83 FR 49022

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Anthony C. Taube,

Phone:

240 420-4565,

Fax:

703 261-8625,

Email: anthony.taube@fda.hhs.gov

RIN:

0910-AF61

90. Laser Products; Amendment to Performance Standard

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

21 U.S.C. 360hh to 360ss; 21 U.S.C. 371; 21 U.S.C. 393

Abstract:

On June 24, 2013, FDA issued a proposed rule that would have amended the performance standard for laser products to achieve closer harmonization between the current standard and the amended International Electrotechnical Commission (IEC) standard for laser products and medical laser products. FDA does not plan to finalize the 2013 proposal.

Completed:

Reason

Date

FR Cite

NPRM; Withdrawal

11/01/18

83 FR 54891

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Erica Payne,

Phone:

301 796-3999,

Fax:

301 847-8145,

Email: erica.payne@fda.hhs.gov

RIN:

0910-AF87

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Centers for Medicare & Medicaid Services (CMS)

Proposed Rule Stage

91. Requirements for Long-Term Care Facilities: Regulatory Provisions To Promote Program Efficiency, Transparency, and Burden Reduction (CMS-3347-P) (Section 610 Review)

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

Secs.1819 and 1919 of the Social Security Act; sec.1819(d)(4)(B) and 1919(d)(4)(B) of the Social Security Act; sec. 1819(b)(1)(A) and 1919 (b)(1)(A) of the Social Security Act

Abstract:

This proposed rule would reform the requirements that long-term care facilities must meet to participate in the Medicare and Medicaid programs, that CMS has identified as unnecessary, obsolete, or excessively burdensome on facilities. This rule would increase the ability of healthcare professionals to devote resources to improving resident care by eliminating or reducing requirements that impede quality care or that divert resources away from providing high quality care.

Timetable:

Action

Date

FR Cite

NPRM

05/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Ronisha Blackstone, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality, MS: S3-02-01, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-6882,

Email: ronisha.blackstone@cms.hhs.gov

RIN:

0938-AT36

92. CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B (CMS-1715-P) (Section 610 Review)

E.O. 13771 Designation:

Other.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1395hh

Abstract:

This annual proposed rule would revise payment polices under the Medicare physician fee schedule, and make other policy changes to payment under Medicare Part B. These changes would apply to services furnished beginning January 1, 2020. Additionally, this rule proposes updates to the Quality Payment Program.

Timetable:

Action

Date

FR Cite

NPRM

06/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Marge Watchorn, Deputy Director, Division of Practitioner Services, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-01-15, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-4361,

Email: marge.watchorn@cms.hhs.gov

RIN:

0938-AT72

93. Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals; the Long-Term Care Hospital Prospective Payment System; and FY 2020 Rates (CMS-1716-F) (Section 610 Review)

E.O. 13771 Designation:

Other.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1395hh

Abstract:

This annual final rule revises the Medicare hospital inpatient and long-term care hospital prospective payment systems for operating and capital-related costs. This rule would implements changes arising from our continuing experience with these systems. In addition, the rule establishes new requirements or revises existing requirements for quality reporting by specific Medicare providers.

Timetable:

Action

Date

FR Cite

NPRM

05/03/19

84 FR 19158

NPRM Comment Period End

06/24/19

Final Action

08/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Donald Thompson, Director, Division of Acute Care,

Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-08-06, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-6504,

Email: donald.thompson@cms.hhs.gov

RIN:

0938-AT73

94. CY 2020 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1717-P) (Section 610 Review)

E.O. 13771 Designation:

Other.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1395hh

Abstract:

This annual proposed rule would revise the Medicare hospital outpatient prospective payment system to implement statutory requirements and changes arising from our continuing experience with this system. The proposed rule describes changes to the amounts and factors used to determine payment rates for services. In addition, the rule proposes changes to the ambulatory surgical center payment system list of services and rates. This proposed rule would also update and refine the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program.

Timetable:

Action

Date

FR Cite

NPRM

06/00/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Elise Barringer, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-03-06, 7500 Security Blvd., Baltimore, MD 21244,

Phone:

410 786-9222,

Email: elise.barringer@cms.hhs.gov

RIN:

0938-AT74

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Centers for Medicare & Medicaid Services (CMS)

Final Rule Stage

95. Hospital and Critical Access Hospital (CAH) Changes To Promote Innovation, Flexibility, and Improvement in Patient Care (CMS-3295-F) (Rulemaking Resulting From a Section 610 Review)

E.O. 13771 Designation:

Regulatory.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1395hh and 1395rr

Abstract:

This final rule updates the requirements that hospitals and critical access hospitals (CAHs) must meet to participate in the Medicare and Medicaid programs. These final requirements are intended to conform the requirements to current standards of practice and support improvements in quality of care, reduce barriers to care, and reduce some issues that may exacerbate workforce shortage concerns.

Timetable:

Action

Date

FR Cite

NPRM

06/16/16

81 FR 39447

NPRM Comment Period End

08/15/16

Final Action—To Be Merged With 0938-AS59 and 0938-AT23

06/00/19

Regulatory Flexibility Analysis Required:

No.

Agency Contact:

CAPT Scott Cooper, Senior Technical Advisor, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality, Mail Stop S3-01-02, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-9465,

Email: scott.cooper@cms.hhs.gov.

RIN:

0938-AS21

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Centers for Medicare & Medicaid Services (CMS)

Long-Term Actions

96. Durable Medical Equipment Fee Schedule, Adjustments To Resume the Transitional 50/50 Blended Rates To Provide Relief in Non-Competitive Bidding Areas (CMS-1687-F) (Section 610 Review)

E.O. 13771 Designation:

Fully or Partially Exempt.

Legal Authority:

42 U.S.C. 1302, 1395hh, and 1395rr(b)(l)); Pub. L. 114-255, sec. 5004(b), 16007(a) and 16008

Abstract:

This final rule follows the interim final rule that published May 11, 2018, and extended the end of the transition period from June 30, 2016, to December 31, 2016 for phasing in adjustments to the fee schedule amounts for certain durable medical equipment (DME) and enteral nutrition paid in areas not subject to the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Competitive Bidding Program (CBP). In addition, the interim rule amended the regulation to resume the transition period for items furnished from August 1, 2017, through December 31, 2018. The interim rule also made technical amendments to existing regulations for DMEPOS items and services to exclude infusion drugs used with DME from the DMEPOS CBP.

Timetable:

Action

Date

FR Cite

Interim Final Rule

05/11/18

83 FR 21912

Interim Final Rule Comment Period End

07/09/18

Final Action

05/00/21

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Alexander Ullman, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C5-07-26, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-9671,

Email: alexander.ullman@cms.hhs.gov.

RIN:

0938-AT21

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Centers for Medicare & Medicaid Services (CMS)

Completed Actions

97. CY 2019 Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System, Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) (CMS-1691-F) (Completion of a Section 610 Review)

E.O. 13771 Designation:

Regulatory.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1395d(d); 42 U.S.C. 1395f(b); 42 U.S.C 1395g

Abstract:

This annual final rule updates the bundled payment system for ESRD facilities by January 1, 2019. The rule also updates the quality incentives in the ESRD program and implements changes to the DMEPOS competitive bidding program.

Timetable:

Action

Date

FR Cite

NPRM

07/19/18

83 FR 34304

NPRM Comment Period End

09/10/18

Final Action

11/14/18

83 FR 56922

Final Action Effective

01/01/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Janae James, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C5-05-27, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-0801,

Email: janae.james@cms.hhs.gov.

RIN:

0938-AT28

98. CY 2019 Home Health Prospective Payment System Rate Update and CY 2020 Case-Mix Adjustment Methodology Refinements; Value-Based Purchasing Model; Quality Reporting Requirements (CMS-1689-FC) (Completion of a Section 610 Review)

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1315a; 42 U.S.C. 1395(hh)

Abstract:

This annual final rule updates the payment rates under the Medicare prospective payment system for home health agencies. In addition, this rule finalizes changes to the Home Health Value-Based Purchasing (HHVBP) Model and to the Home Health Quality Reporting Program (HH QRP).

Timetable:

Action

Date

FR Cite

NPRM

07/12/18

83 FR 32340

NPRM Comment Period End

08/31/18

Final Action

11/13/18

83 FR 56406

Comment Period End

12/31/18

Final Action Effective

01/01/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Hillary Loeffler, Director, Division of Home Health and Hospice, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C5-08-28, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-0456,

Email: hillary.loeffler@cms.hhs.gov.

RIN:

0938-AT29

99. CY 2019 Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates (CMS-1695-FC) (Completion of a Section 610 Review)

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1395hh

Abstract:

This annual final rule revises the Medicare hospital outpatient prospective payment system to implement statutory requirements and changes arising from our continuing experience with this system. The rule describes changes to the amounts and factors used to determine payment rates for services. In addition, the rule finalizes changes to the ambulatory surgical center payment system list of services and rates. This rule updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program.

Timetable:

Action

Date

FR Cite

NPRM

07/31/18

83 FR 37046

NPRM Comment Period End

09/24/18

Final Action

11/21/18

83 FR 58818

Final Action Effective

01/01/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Marjorie Baldo, Health Insurance Specialist, Department of Health and Human Services, Centers for Medicare & Medicaid Services, Center for Medicare, MS: C4-03-06, 7500 Security Boulevard, Baltimore, MD 21244,

Phone:

410 786-4617,

Email: marjorie.baldo@cms.hhs.gov.

RIN:

0938-AT30

100. CY 2019 Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Medicare Part B and the Quality Payment Program (CMS-1693-F) (Completion of a Section 610 Review)

E.O. 13771 Designation:

Deregulatory.

Legal Authority:

42 U.S.C. 1302; 42 U.S.C. 1395hh

Abstract:

This annual final rule revises payment polices under the Medicare physician fee schedule, and makes other policy changes to payment under Medicare Part B. These changes apply to services furnished beginning January 1, 2019. Additionally, this rule updates the Quality Payment Program.

Timetable:

Action

Date

FR Cite

NPRM

07/27/18

83 FR 35704

NPRM Comment Period End

09/10/18

Final Action

11/23/18

83 FR 59836

Final Action Effective

01/01/19

Regulatory Flexibility Analysis Required:

Yes.

Agency Contact:

Phone:

410 786-4361,

Email: marge.watchorn@cms.hhs.gov.

RIN:

0938-AT31

[FR Doc. 2019-12004 Filed 6-21-19; 8:45 am]

BILLING CODE 4150-03-P

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.